Editas Medicine to Participate in Upcoming Investor Conferences
January 31 2024 - 8:00AM
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome
editing company, today announced that management will participate
in the following upcoming investor conferences to discuss the
Company and its programs, including reni-cel:
- Guggenheim 6th Annual Biotechnology
ConferenceFormat: Fireside ChatDate: Wednesday, February
7Time: 9:30 a.m. ETLocation: New York, NY
- Oppenheimer 34th Annual Healthcare Life Sciences
ConferenceFormat: Fireside ChatDate: Tuesday, February
13Time: 8:40 a.m. ETLocation: Virtual
To access the live webcasts of Editas Medicine’s
presentations, please visit the “Investors” section of the
Company’s website at www.editasmedicine.com. An archived replay
will be available for approximately 30 days following each
event.
About Editas MedicineAs a
clinical-stage genome editing company, Editas Medicine is focused
on translating the power and potential of the CRISPR/Cas12a and
CRISPR/Cas9 genome editing systems into a robust pipeline of
treatments for people living with serious diseases around the
world. Editas Medicine aims to discover, develop, manufacture, and
commercialize transformative, durable, precision genomic medicines
for a broad class of diseases. Editas Medicine is the exclusive
licensee of Broad Institute’s Cas12a patent estate and Broad
Institute and Harvard University’s Cas9 patent estates for human
medicines. For the latest information and scientific presentations,
please visit www.editasmedicine.com.
Media and Investor Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Apr 2024 to May 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From May 2023 to May 2024